A Phase II Evaluation Of Epothilone-B BMS 247550 [ixabepilone] (IND 59,669 NSC 710428) In The Treatment Of Recurrent Or Persistent Platinum And Paclitaxel Refractory Ovarian Or Primary Peritoneal Cancer.

Trial Profile

A Phase II Evaluation Of Epothilone-B BMS 247550 [ixabepilone] (IND 59,669 NSC 710428) In The Treatment Of Recurrent Or Persistent Platinum And Paclitaxel Refractory Ovarian Or Primary Peritoneal Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2015

At a glance

  • Drugs Ixabepilone (Primary)
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Mar 2010 Actual end date (Mar 2010) and actual number of patients (51) added as reported by ClinicalTrials.gov.
    • 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top